for patients
understanding Hyperinsulinism
Focused on substantially improving the quality of life for individuals living with hyperinsulinism.
There are multiple forms of hyperinsulinism (HI) that can result in hypoglycemia. Congenital HI primarily affects infants and children, while tumor HI generally impacts adults with insulinomas or non-islet cell tumors (NICT). Despite the persistent and dangerous nature of hypoglycemia in these populations, today’s treatment options are limited, often ineffective, and poorly tolerated.
This critical gap leaves many patients vulnerable to recurrent, unpredictable hypoglycemic lows, highlighting the urgent need for innovative, effective therapies.
The Rezolution empowers families, fosters meaningful connections, and drives toward a shared rezolution for better care and brighter futures for the HI community.
Congenital Hyperinsulinism
Most children with cHI begin showing signs in the first week of life. These early symptoms can be hard to recognize, but they are related to the brain not having enough fuel (blood glucose or ketones, another important energy source). If not detected and treated early, severe or repeated episodes of hypoglycemia can cause permanent brain injury, seizures, developmental delays, or learning difficulties that impact the patient and family for the rest of their lives.
For many patients, the treatments we have today don’t work well enough. The early years of life with cHI demand constant vigilance from caregivers to prevent dangerous hypoglycemia, creating an exhausting burden that impacts not only immediate well-being but also the long-term quality of life for both patients and families.
Tumor Hyperinsulinism
Non-islet cell tumor hypoglycemia (NICTH), sometimes called “Doege-Potter syndrome” or “paraneoplastic hypoglycemia,” is a rare condition where certain tumors outside the pancreas make too much hormone growth factors that can act like insulin and are able to decrease blood sugar below the normal level.
With both tumor types, patients are sometimes misdiagnosed or go through many tests before answers are found. Unfortunately, these delays can put patients at risk of ongoing low blood sugars that may cause lasting harm to the brain. Early recognition of the condition is key to improving outcomes and reducing these risks.
Ersodetug is an insulin receptor modulating antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any form of HI.
When no approved treatments are available, some patients may qualify for compassionate use, also called an Expanded Access Program (EAP). Rezolute supports EAPs to help patients with serious conditions access investigational therapies like ersodetug. An investigational therapy is one that is being studied but has not yet been approved for any use by any health authority.
Our EAP is designed for patients who benefited from ersodetug during clinical trials and wish to continue treatment, or for those with severe, frequent low blood sugar due to high insulin levels who have no other options.
If you think you may qualify, talk to your healthcare provider, or contact us at: [email protected]
patient voices
This video, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “prove,” “potential,” “seek,” “strive,” “try,” or future or conditional verbs such as “predict,” “could,” “may,” “likely,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Viewers are cautioned not to place undue reliance on these forward-looking statements, which speak only as an individual patient. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov.
You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. This video shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
patient presentations and publications
Join the Rezolution
Be a part of the movement. Complete this form to stay up to date on therapy innovations, events, and educational resources.
"(Required)" indicates required fields